Antiretroviral Therapy for Control of the HIV-associated Tuberculosis Epidemic in Resource-limited Settings

Overview

Journal Clin Chest Med

Specialty Pulmonary Medicine

Date 2009 Nov 21

PMID 19925961

Citations 66

Authors

Stephen D Lawn

Katharina Kranzer

Robin Wood

Affiliations

Soon will be listed here.

Abstract

Great progress has been made over the past few years in HIV testing in patients who have tuberculosis (TB) and in the scale-up of antiretroviral therapy. More than 3 million people in resource-limited settings were estimated to have started antiretroviral therapy by the end of 2007 and 2 million of these were in sub-Saharan Africa. However, little is known about what impact this massive public health intervention will have on the HIV-associated TB epidemic or how antiretroviral therapy might be used to best effect TB control. This article provides an in-depth review of these issues.

Citing Articles

Incidence Rate and Risk Factors for Developing Active Tuberculosis Among People Living With HIV in Georgia 2019-2020 Cohort.

Buziashvili M, Djibuti M, Tukvadze N, DeHovitz J, Baliashvili D Open Forum Infect Dis. 2024; 11(9):ofae466.

PMID: 39257676 PMC: 11384916. DOI: 10.1093/ofid/ofae466.

The trajectories of CD4 T lymphocytes over time in patients who have defaulted on treatment for tuberculosis in a cohort of people living with HIV, Recife/PE.

Cunha R, Filho D, M Albuquerque M, Lacerda H, Diniz G, Montarroyos U PLoS One. 2024; 19(3):e0299244.

PMID: 38478483 PMC: 10936822. DOI: 10.1371/journal.pone.0299244.

Association of Toll-Like Receptor Gene Polymorphisms with Tuberculosis in HIV-Positive Participants.

Salamaikina S, Korchagin V, Kulabukhova E, Mironov K, Zimina V, Kravtchenko A Epigenomes. 2023; 7(3).

PMID: 37606452 PMC: 10443360. DOI: 10.3390/epigenomes7030015.

Incidence and predictors of Tuberculosis among patients enrolled in Anti-Retroviral Therapy after universal test and treat program, Addis Ababa, Ethiopia. A retrospective follow -up study.

Getu A, Wolde H, Animut Y, Kibret A PLoS One. 2022; 17(8):e0272358.

PMID: 35921384 PMC: 9348662. DOI: 10.1371/journal.pone.0272358.

Prevalence and associated risk factors for tuberculosis among people living with HIV in Nepal.

Adhikari N, Bhattarai R, Basnet R, Joshi L, Tinkari B, Thapa A PLoS One. 2022; 17(1):e0262720.

PMID: 35089953 PMC: 8797228. DOI: 10.1371/journal.pone.0262720.

References

Golub J, Saraceni V, Cavalcante S, Pacheco A, Moulton L, King B . The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007; 21(11):1441-8. PMC: 3063947. DOI: 10.1097/QAD.0b013e328216f441. View

De Cock K, Chaisson R . Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis. 1999; 3(6):457-65. View

Badri M, Wilson D, Wood R . Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002; 359(9323):2059-64. DOI: 10.1016/S0140-6736(02)08904-3. View

Lawn S, Wood R . How can earlier entry of patients into antiretroviral programs in low-income countries be promoted?. Clin Infect Dis. 2006; 42(3):431-2. DOI: 10.1086/499527. View

Lawn S, Wood R . Tuberculosis control in South Africa--will HAART help?. S Afr Med J. 2006; 96(6):502-4. View

Lawn S, Bekker L, Middelkoop K, Myer L, Wood R . Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis. 2006; 42(7):1040-7. DOI: 10.1086/501018. View

Lawn S, Myer L, Orrell C, Bekker L, Wood R . Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005; 19(18):2141-8. DOI: 10.1097/01.aids.0000194802.89540.e1. View

Golub J, Durovni B, King B, Cavalacante S, Pacheco A, Moulton L . Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2008; 22(18):2527-33. PMC: 2603140. DOI: 10.1097/QAD.0b013e328311ac4e. View

Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X . Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med. 2005; 172(1):123-7. DOI: 10.1164/rccm.200410-1342OC. View

10.

Lawn S, Little F, Bekker L, Kaplan R, Campbel E, Orrell C . Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2008; 23(3):335-42. PMC: 3776050. DOI: 10.1097/QAD.0b013e328321823f. View

11.

Fairall L, Bachmann M, Louwagie G, van Vuuren C, Chikobvu P, Steyn D . Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med. 2008; 168(1):86-93. DOI: 10.1001/archinternmed.2007.10. View

12.

Panjabi R, Comstock G, Golub J . Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis. 2007; 11(8):828-37. View

13.

Lawn S, Wilkinson R, Lipman M, Wood R . Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med. 2008; 177(7):680-5. PMC: 2277208. DOI: 10.1164/rccm.200709-1311PP. View

14.

Gandhi N, Moll A, Sturm A, Pawinski R, Govender T, Lalloo U . Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368(9547):1575-80. DOI: 10.1016/S0140-6736(06)69573-1. View

15.

Sonnenberg P, Glynn J, Fielding K, Murray J, Godfrey-Faussett P, Shearer S . How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2004; 191(2):150-8. DOI: 10.1086/426827. View

16.

Zachariah R, Fitzgerald M, Massaquoi M, Acabu A, Chilomo D, Salaniponi F . Does antiretroviral treatment reduce case fatality among HIV-positive patients with tuberculosis in Malawi?. Int J Tuberc Lung Dis. 2007; 11(8):848-53. View

17.

Perriens J, St Louis M, Mukadi Y, Brown C, Prignot J, Pouthier F . Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med. 1995; 332(12):779-84. DOI: 10.1056/NEJM199503233321204. View

18.

Lawn S, Myer L, Edwards D, Bekker L, Wood R . Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009; 23(13):1717-25. PMC: 3801095. DOI: 10.1097/QAD.0b013e32832d3b6d. View

19.

Holmes C, Wood R, Badri M, Zilber S, Wang B, Maartens G . CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006; 42(4):464-9. DOI: 10.1097/01.qai.0000225729.79610.b7. View

20.

Akksilp S, Karnkawinpong O, Wattanaamornkiat W, Viriyakitja D, Monkongdee P, Sitti W . Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis. 2008; 13(7):1001-7. PMC: 2878231. DOI: 10.3201/eid1307.061506. View